Corrections: Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial (The Lancet Infectious Diseases (2016) 16(1) (31–42) (S147330991500362X)(10.1016/S1473-3099(15)00362-X));Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial

The Lancet Infectious Diseases

Volumn 16, Issue 1, 2016, Pages 31-42

  Tapia, Milagritos D ^a,b   Sow, Samba O ^b   Lyke, Kirsten E ^a   Haidara, Fadima Cheick ^b   Diallo, Fatoumata ^b   Doumbia, Moussa ^b   Traore, Awa ^b   Coulibaly, Flanon ^b   Kodio, Mamoudou ^b   Onwuchekwa, Uma ^b   Sztein, Marcelo B ^a   Wahid, Rezwanul ^a   Campbell, James D ^a   Kieny, Marie Paule ^c   Moorthy, Vasee ^c   Imoukhuede, Egeruan B ^d,e   Rampling, Tommy ^d,e   Roman, Francois ^f   De Ryck, Iris ^f   Bellamy, Abbie R ^g   Dally, Len ^g   Mbaya, Olivier Tshiani ^h   Ploquin, Aurélie ^h   Zhou, Yan ^h   Stanley, Daphne A ^h   Bailer, Robert ^h   Koup, Richard A ^h   Roederer, Mario ^h   Ledgerwood, Julie ^h   Hill, Adrian V S ^d,e   Ballou, W Ripley ^f   Sullivan, Nancy ^h   Graham, Barney ^h   Levine, Myron M ^a   more..

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b Centre Pour le Développement des Vaccins CVD Mali   (Mali)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^f GSK   (Belgium)

^g EMMES CORPORATION   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHIMPANZEE ADENOVIRUS 3 VECTOR ZAIRE EBOLA VIRUS GLYCOPROTEIN; EBOLA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; MODIFIED VACCINIA ANKARA ZAIRE EBOLA VIRUS GLYCOPROTEIN FILOVIRUS ANTIGEN; NEUTRALIZING ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; GLYCOPROTEIN; VIRUS ANTIGEN;

ADULT; ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MALI; MALIAN; MARYLAND; MYALGIA; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TREATMENT OUTCOME; VACCINATION; VACCINE IMMUNOGENICITY; ADOLESCENT; AGED; ANIMAL; CLINICAL TRIAL; DOSE RESPONSE; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; MIDDLE AGED; SECONDARY IMMUNIZATION; UNITED STATES; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIGENS, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; EBOLA VACCINES; FEMALE; GLYCOPROTEINS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION, SECONDARY; MALE; MALI; MIDDLE AGED; SINGLE-BLIND METHOD; UNITED STATES; YOUNG ADULT;

EID: 84959184825     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00505-8     Document Type: Erratum

References (25)

1. Baize, S, Pannetier, D, Oestereich, L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371 (2014), 1418–1425.
2. The Lancet Infectious Diseases. Rationality and coordination for Ebola outbreak in west Africa. Lancet Infect Dis, 14, 2014, 1163.
3. WHO Ebola Response Team. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med 371 (2014), 1481–1495.
4. Briand, S, Bertherat, E, Cox, P, et al. The international Ebola emergency. N Engl J Med 371 (2014), 1180–1183.
5. Sullivan, NJ, Martin, JE, Graham, BS, Nabel, GJ, Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 7 (2009), 393–400.
6. Geisbert, TW, Feldmann, H, Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 204:suppl 3 (2011), S1075–S1081.
7. Levine, MM, Tapia, M, Hill, AV, Sow, SO, How the current West African Ebola virus disease epidemic is altering views on the need for vaccines and is galvanizing a global effort to field-test leading candidate vaccines. J Infect Dis 211 (2015), 504–507.
8. Kanapathipillai, R, Henao Restrepo, AM, Fast, P, et al. Ebola vaccine—an urgent international priority. N Engl J Med 371 (2014), 2249–2251.
9. Stanley, DA, Honko, AN, Asiedu, C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebolavirus challenge. Nat Med 20 (2014), 1126–1129.
10. Rampling, T, Ewer, K, Bowyer, G, et al. A monovalent chimpanzee adenovirus Ebola vaccine—preliminary report. N Engl J Med, 2015, 10.1056/NEJMoa1411627 published online Jan 28.
11. Ledgerwood, JE, DeZure, AD, Stanley, DA, et al. Chimpanzee adenovirus vector Ebola vaccine—preliminary report. N Engl J Med, 2014, 10.1056/NEJMoa1410863 published online Nov 26.
12. Sullivan, NJ, Geisbert, TW, Geisbert, JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med, 3, 2006, e177.
13. Paris, R, Kuschner, RA, Binn, L, et al. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors. Clin Vaccine Immunol 21 (2014), 783–786.
14. Sarwar, UN, Costner, P, Enama, ME, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis 211 (2015), 549–557.
15. Roederer, M, Nozzi, JL, Nason, MC, SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79 (2011), 167–174.
16. Plotkin, SA, Gilbert, PB, Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 54 (2012), 1615–1617.
17. Sullivan, NJ, Hensley, L, Asiedu, C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 17 (2011), 1128–1131.
18. Foege, WH, Millar, JD, Henderson, DA, Smallpox eradication in west and central Africa. Bull World Health Organ 52 (1975), 209–222.
19. Foege, WH, Millar, JD, Lane, JM, Selective epidemiologic control in smallpox eradication. Am J Epidemiol 94 (1971), 311–315.
20. Henao-Restrepo, AM, Longini, IM, Egger, M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386 (2015), 857–866.
21. Agnandji, ST, Huttner, A, Zinser, ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe—preliminary report. N Engl J Med, 2015, 10.1056/NEJMoa1502924 published online April 1.
22. Barnes, E, Folgori, A, Capone, S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med, 4, 2012, 115ra1.
23. WHO. Ebola vaccine chosen for second round of testing in the Guinea efficacy trial. http://www.who.int/medicines/ebola-treatment/2nd-vax-trial-test_guinea/en (accessed Sept 11, 2015).
24. WHO. Ebola situation report. http://apps.who.int/iris/bitstream/10665/184623/1/ebolasitrep_16Sept2015_eng.pdf?ua=1, Sept 16, 2015 (accessed Sept 17, 2015).
25. Kibuuka, H, Berkowitz, NM, Millard, M, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 385 (2015), 1545–1554.